Hemanext
Lexington, US · Delaware corporation · 5 known investors
Find your way into Hemanext
683 people in our graph share verified history with the Hemanext team — schools, employers, funds. One of them is your warm intro.
Hemanext develops oxygen-controlled storage technology to preserve red blood cell quality and function during transfusion storage. The company serves hospitals and blood establishments seeking to improve patient outcomes in transfusion medicine.
Founders & leadership




Board
Investors · 5
Also in the syndicate · 5
Funding
SEC filings, press & company announcements$122.3M disclosed across 8 of 10 rounds · 2016–2025
- Undisclosed amountSeries ASep 2021
Antaeus Enterprises, Inc., Grabe Family Office, Omega Family Office, The Eduardo Avayu Family Office, The Testa Family Office
Source ↗
▶$20MraisedAug 2025 · 29 investors · Other Health CareRule 506(b)
- Robert HaimeExecutive Officer
- Eric J. NewmanExecutive Officer
- Peter TestaDirector
- Daan KokExecutive Officer
- Paul M. NessDirector
- Geoffrey CrouseDirector
- Andrew DunhamExecutive Officer, Director
- Laura DanielsExecutive Officer
- Eduardo AvayuDirector
- Philip PeadDirector
- Stephen A. EckertDirector
- Joseph GroganDirector
- Laurel OmertExecutive Officer
- Ismail KolaDirector
- William Patrick O'NeillDirector
- Jill BuckleyExecutive Officer
- Offering amount
- $24M
- Amount sold
- $20M
- Sales commissions
- $41.3K
- Placement agents
- Octavian AG
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$21.7MraisedJul 2025 · 51 investors · Other Health CareRule 506(b)
- Stephen A. EckertDirector
- Philip PeadDirector
- Geoffrey CrouseDirector
- William Patrick O'NeillDirector
- Jill BuckleyExecutive Officer
- Eduardo AvayuDirector
- Peter TestaDirector
- Daan KokExecutive Officer
- Robert HaimeExecutive Officer
- Paul M. NessDirector
- Ismail KolaDirector
- Andrew DunhamExecutive Officer, Director
- Eric J. NewmanExecutive Officer
- Joseph GroganDirector
- Laura DanielsExecutive Officer
- Laurel OmertExecutive Officer
- Offering amount
- $21.7M
- Amount sold
- $21.7M
- Sales commissions
- $27.2K
- Placement agents
- Octavian AG
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedJan 2024 · 10 investors · Other Health CareRule 506(b)
- Stephen A. EckertDirector
- Paul M. NessDirector
- Andrew DunhamExecutive Officer, Director
- Robert HaimeExecutive Officer
- Laurel OmertExecutive Officer
- Michael David TestaDirector
- Laura DanielsExecutive Officer
- Daan KokExecutive Officer
- William Patrick O'NeillDirector
- Eduardo AvayuDirector
- Ismail KolaDirector
- Eric J. NewmanExecutive Officer
- Jill BuckleyExecutive Officer
- Richard PerleDirector
- Offering amount
- $10M
- Amount sold
- $5M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.3MraisedNov 2023 · 20 investors · Other Health CareRule 506(b)
- Jill BuckleyExecutive Officer
- Andrew DunhamExecutive Officer, Director
- William Patrick O'NeillDirector
- Daan KokExecutive Officer
- Laurel OmertExecutive Officer
- Laura DanielsExecutive Officer
- Ismail KolaDirector
- Richard PerleDirector
- Eduardo AvayuDirector
- Stephen A. EckertDirector
- Robert HaimeExecutive Officer
- Paul M. NessDirector
- Eric NewmanExecutive Officer
- Michael David TestaDirector
- Offering amount
- $11.3M
- Amount sold
- $11.3M
- Finders' fees
- $400K
- Placement agents
- Sonenshine & Company LLC
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.2MraisedFeb 2023 · 38 investors · Other Health CareRule 506(b)
- Martin A. CannonExecutive Officer, Director
- Daan KokExecutive Officer
- Eric NewmanExecutive Officer
- Michael David TestaDirector
- Guy CoganDirector
- Andrew DunhamExecutive Officer
- William Patrick O'NeillDirector
- Kimberly DorschExecutive Officer
- Jill BuckleyExecutive Officer
- Ismail KolaDirector
- Eduardo AvayuDirector
- Richard PerleDirector
- Robert HaimeExecutive Officer
- Paul M. NessDirector
- Alex MarichalExecutive Officer
- Stephen EckertDirector
- Laurel OmertExecutive Officer
- Laura DanielsExecutive Officer
- Offering amount
- $15M
- Amount sold
- $13.2M
- Finders' fees
- $1.1M
- Placement agents
- Sonenshine & Company LLC
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$39.6MraisedOct 2021 · 39 investors · BiotechnologyRule 506(b)
- Eric NewmanExecutive Officer
- Guy CoganDirector
- Laura DanielsExecutive Officer
- Michael David TestaDirector
- William Patrick O'NeillDirector
- Andrew DunhamExecutive Officer
- Laurel OmertExecutive Officer
- Eduardo AvayuDirector
- Stephen EckertDirector
- Richard PerleDirector
- Jill BuckleyExecutive Officer
- Robert HaimeExecutive Officer
- Alex MarichalExecutive Officer
- Paul M. NessDirector
- Martin A. CannonExecutive Officer, Director
- Offering amount
- $59.5M
- Amount sold
- $39.6M
- Finders' fees
- $1.1M
- Placement agents
- Sonenshine & Company LLC
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.8MraisedOct 2018 · 6 investors · BiotechnologyRule 506(b)
- Richard PerleDirector
- Martin A. CannonExecutive Officer, Director
- Stephen EckertDirector
- Guy CoganDirector
- David HermanDirector
- Eric NewmanExecutive Officer
- Michael David TestaDirector
- Joseph BarrettExecutive Officer
- Offering amount
- $16M
- Amount sold
- $8.8M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedDec 2017 · 6 investors · BiotechnologyRule 506(b)
- Martin A. CannonExecutive Officer, Director
- Michael David TestaDirector
- David HermanDirector
- Lynn MallettExecutive Officer
- Joseph BarrettExecutive Officer
- Guy CoganDirector
- Stephen EckertDirector
- Richard PerleDirector
- Offering amount
- $5M
- Amount sold
- $2.7M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapCompanies competing with Hemanext for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Hemanext do?
- Hemanext develops oxygen-controlled storage technology to preserve red blood cell quality and function during transfusion storage. The company serves hospitals and blood establishments seeking to improve patient outcomes in transfusion medicine.
- Who founded Hemanext?
- Hemanext was founded by Martin Cannon.
- How much funding has Hemanext raised?
- Hemanext has disclosed $122.3M raised across 8 of its 10 known rounds.
- Where is Hemanext headquartered?
- Hemanext is headquartered in Lexington, US.



